STARCOIN GROUP LIMITED
星太鏈集團有限公司

(Formerly known as Innovative Pharmaceutical Biotech Limited 領航醫藥及生物科技有限公司)
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 399)

SUPPLEMENTAL ANNOUNCEMENT
DECISION OF THE LISTING REVIEW COMMITTEE

This announcement is made by Starcoin Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of The Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 29 April 2026 (the "**Announcement**") in relation to the decision of the Listing Review Committee. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as defined in the Announcement.

DECISION OF THE LISTING REVIEW COMMITTEE

According to the letter form the Listing Review Committee received by the Company on 28 April 2026, the Listing Review Committee arrived at its decision for the following reasons:

1. **On operations** — The core oral insulin product has seen no material progress in clinical trials since 2014. The Listing Review Committee noted that even assuming future recruitments, the Company lacked a concrete plan to meet its June 2027 completion target. Beyond recruitment delays, the Listing Review Committee highlighted significant uncertainties regarding whether the clinical results would meet standards and if the National Medical Products Administration (NMPA) would grant the necessary certificates. The Listing Review Committee further considered that the trading, health supplements, and blockchain businesses lacked scale, track record, or proven revenue generating capability.

2. **On assets and financing** — While the Company held HK$1.1 billion in total assets (mostly intangible assets related to the product), it faced HK$1.1 billion in net current liabilities. This included HK$1 billion in convertible bonds owed to Extrawell Pharmaceutical Holdings Limited ("**Extrawell**") (the "**Convertible Bonds**"). Although the Company had entered into a deed of amendment with Extrawell to, amongst others, extend the maturity date of the Convertible Bonds from July 2025 to July 2030, the Listing Review Committee noted that the proposed amendment was subject to approval by shareholders of both the Company and Extrawell, as well as the Stock Exchange. In addition, the Company relied heavily on its substantial shareholder and lacked concrete alternative financing plans.

In light of the above, the Listing Review Committee concluded that the Company had failed to maintain a sufficient level of operations and assets of sufficient value to support its operations to warrant the continued listing of its shares, in compliance with Rule 13.24 of the Listing Rules. Accordingly, the Listing Review Committee decided to uphold the Decision of Listing Committee to suspend the Company's shares under Rule 6.01(3) of the Listing Rules.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Starcoin Group Limited
Yeung Yung
Chairman

Hong Kong, 30 April 2026

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: www.starcoingroup.com and www.irasia.com/listco/hk/starcoingroup.